Abstract
Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical.
Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.
Keywords: Pancreatic cancer, biomarker, tumor progression, risk factor, CA 19-9
Current Pharmaceutical Design
Title:Advances in Biomarker Research for Pancreatic Cancer
Volume: 18 Issue: 17
Author(s): Kruttika Bhat, Fengfei Wang, Qingyong Ma, Qinyu Li, Sanku Mallik, Tze-chen Hsieh and Erxi Wu
Affiliation:
Keywords: Pancreatic cancer, biomarker, tumor progression, risk factor, CA 19-9
Abstract: Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical.
Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.
Export Options
About this article
Cite this article as:
Bhat Kruttika, Wang Fengfei, Ma Qingyong, Li Qinyu, Mallik Sanku, Hsieh Tze-chen and Wu Erxi, Advances in Biomarker Research for Pancreatic Cancer, Current Pharmaceutical Design 2012; 18 (17) . https://dx.doi.org/10.2174/13816128112092439
DOI https://dx.doi.org/10.2174/13816128112092439 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Analytic strategies to evaluate the association of time-varying exposures to HIV-related outcomes: Alcohol consumption as an example
Current HIV Research Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins
Current Pharmaceutical Design Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Investigating the Molecular Basis of Drug Action and Response: Chemocentric Genomics and Proteomics
Current Drug Targets Association of EGF rs4444903 and XPD rs13181 Polymorphisms with Cutaneous Melanoma in Caucasians
Medicinal Chemistry Insulin Resistance, Oxidative Stress and Cardiovascular Complications: Role of Sirtuins
Current Pharmaceutical Design Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
Current Medicinal Chemistry Medical Data Assessment with Traditional, Machine-learning and Deeplearning Techniques
Current Medical Imaging Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation The Complex Biology of FOXO
Current Drug Targets Nanostructured Therapeutic Systems of PUFAs for the Treatment of Glioblastoma Multiforme
Current Drug Metabolism Vitamin-D in the Immune System: Genomic and Non-Genomic Actions
Mini-Reviews in Medicinal Chemistry Ca2+ Mediates the Adhesion of Breast Cancer Cells in Self-Assembled Multifunctional Microfluidic Chip Prepared with Carbohydrate Beads
Micro and Nanosystems Peptide Nucleic Acids: A Novel Approach
Current Chemical Biology Ideal and Reality: Barricade in the Delivery of Small Interfering RNA for Cancer Therapy
Current Pharmaceutical Biotechnology Cucurbitacin B Enhances the Anticancer Effect of Imatinib Mesylate Through Inhibition of MMP-2 Expression in MCF-7 and SW480 Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Colloidal Drug Delivery Systems in Vaccine Delivery
Current Drug Targets Vacuolar H+-ATPase Signaling Pathway in Cancer
Current Protein & Peptide Science Fluorescent Porphyrin with an Increased Uptake in Peripheral Blood Cell Subpopulations from Colon Cancer Patients
Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets